Personalized Treatment Approaches of Myopathies Based on Antibodies: Suur Bilicier, MD
The associate professor of neurology at the University of Texas Health Science Center at Houston talked about advances in the classification of inflammatory myopathies at the recently concluded 2023 MDA conference. [WATCH TIME: 4 minutes]
WATCH TIME: 4 minutes
“The new classification of inflammatory myopathies [is an important to highlight]. Polymyositis is now becoming rarer; it wasn't as frequent as we thought it was. It's being pushed out or down to the classification, that's one important thing. The second thing is the new knowledge on antibodies in immune mediated myopathies or idiopathic inflammatory myopathies. Each antibody provides more insight for us as to what we need to do for our patients. In another word, it provides a custom customized approach, diagnostic approach and treatment approach for our patients.”
Recently, Suur Bilicier, MD, associate professor of neurology at the University of Texas Health Science Center at Houston, presented a talk on therapeutic approaches in myositis based on antibodies at the
Bilicier, a neuromuscular specialist at UTHealth Houston, McGovern Medical School, sat down with NeurologyLive® in an interview at the conference to provide an overview of the topics discussed in the session. In addition, she discussed the important highlights of the session that neurologists who care for patients with myositis should be informed about. She also talked about the role of antibodies in myositis and tumorigenesis which are currently being explored by researchers.
REFERENCES
1. Bilicier, S. Dermatomyositis: A Diagnostic and Therapeutic Approach Based on Antibodies. Presented at: MDA Clinical & Scientific Conference; March 19-22, 2023; Dallas, TX. Lab to Life: Myositis session.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
- Pathophysiology of Myasthenia Gravis
September 18th 2025